SLDB

Solid Biosciences Inc. Form 8-K Summary

Business Context and Reporting Period

Date of Report: September 29, 2022
Company: Solid Biosciences Inc. (SLDB)
Event: Entry into a Material Definitive Agreement (Merger) and Private Placement of Equity Securities.

On September 29, 2022, Solid Biosciences Inc. entered into an Agreement and Plan of Merger to acquire AavantiBio, Inc., a privately-held gene therapy company focused on Friedreich's Ataxia. Concurrently, the Company executed a Securities Purchase Agreement for a private placement of common stock (PIPE) and announced significant leadership changes and strategic shifts in its clinical pipeline.

Key Financial Metrics and Transaction Terms

• Merger Consideration: AavantiBio shareholders will receive $1,000 in cash and stock consideration equal to 15% of Solid Biosciences' outstanding common stock (pre-closing, fully diluted basis).
• Private Placement (PIPE): The Company agreed to sell 159,574,463 shares of common stock to accredited investors at $0.47 per share.
• Expected Proceeds: Approximately $75.0 million in gross proceeds from the PIPE, subject to fees and expenses.
• Termination Fee: If the Merger Agreement is terminated under specified circumstances, Solid Biosciences may be required to pay AavantiBio a termination fee of $310,000 and reimburse expenses up to $750,000.
• Liquidity: The filing does not provide current cash balance or debt figures; liquidity is expected to be bolstered by the $75.0 million PIPE proceeds upon closing.

Material Changes and Strategic Shifts

• Leadership Transition:
  • Resignations: Ilan Ganot (CEO/President) and Erin Powers Brennan (CLO/Secretary) will resign effective upon the closing of the Merger.
  • Appointments: Alexander (Bo) Cumbo (current CEO of AavantiBio) will become the new President and CEO. Mr. Cumbo and Adam Koppel (Bain Capital Life Sciences) will join the Board.
• Executive Compensation:
  • Mr. Cumbo: Base salary of $585,000; target bonus up to 55% of base; granted options for 3,433,500 shares and RSUs for 1,716,749 shares.
  • Mr. Ganot: Separation package includes 18 months of base salary, 18 months of health coverage, and a lump sum of $477,427 (150% of 2022 target bonus). He will also serve as a consultant for 12 months at $20,833/month.
  • Ms. Brennan: Separation package includes 12 months of base salary, 12 months of health coverage, and a lump sum of $238,306 (100% of 2022 target bonus plus retention bonus). She will serve as a consultant for 9 months at $400/hour.
• Pipeline Strategy:
  • SGT-003: The Company is prioritizing this next-generation AAV gene therapy for Duchenne Muscular Dystrophy (DMD). Non-clinical data showed 2.3-fold higher microdystrophin expression compared to the previous candidate. IND filing is anticipated in mid-2023.
  • SGT-001: Activities for this first-generation candidate are being paused. Interim data from the IGNITE DMD trial showed mixed results, with dystrophin expression dropping to below the limit of quantification at 24 months for one patient.

Guidance, Outlook, and Risks

Outlook: The combined company intends to advance SGT-003 for DMD and AavantiBio's programs (AVB-202 for Friedreich's Ataxia and AVB-401). The Company anticipates initiating patient dosing for SGT-003 in late 2023, subject to IND clearance.

Risks and Contingencies:

• Transaction Completion: The Merger and PIPE are contingent on stockholder approval, Nasdaq listing approval, and satisfaction of closing conditions.
• Regulatory Approval: Success depends on obtaining FDA approvals for SGT-003 and AavantiBio's candidates.
• Capital Needs: The Company faces risks regarding its ability to raise additional capital to fund development and continue as a going concern.
• Nasdaq Compliance: Risks related to maintaining listing status, including minimum bid price requirements.

Investor Verification Checklist

• Verify the final terms of the Merger Agreement and the exact number of shares to be issued to AavantiBio shareholders once the pre-closing share count is finalized.
• Confirm the closing date of the Merger and the PIPE, as the $75.0 million proceeds are contingent on these events.
• Review the definitive proxy statement for details on the voting proposals and the specific dilution impact of the 15% stock consideration and PIPE shares.
• Monitor the status of the SGT-003 IND filing expected in mid-2023 and the rationale for pausing SGT-001.
• Assess the combined company's cash runway post-closing, considering the $75.0 million inflow against the costs of developing multiple gene therapy programs.